"Carcinoma, Bronchogenic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Malignant neoplasm arising from the epithelium of the BRONCHI. It represents a large group of epithelial lung malignancies which can be divided into two clinical groups: SMALL CELL LUNG CANCER and NON-SMALL-CELL LUNG CARCINOMA.
| Descriptor ID |
D002283
|
| MeSH Number(s) |
C04.588.894.797.520.109.220 C08.381.540.140 C08.785.520.100.220
|
| Concept/Terms |
Carcinoma, Bronchogenic- Carcinoma, Bronchogenic
- Bronchogenic Carcinoma
- Bronchogenic Carcinomas
- Carcinomas, Bronchogenic
- Carcinoma, Bronchial
- Bronchial Carcinoma
- Bronchial Carcinomas
- Carcinomas, Bronchial
|
Below are MeSH descriptors whose meaning is more general than "Carcinoma, Bronchogenic".
Below are MeSH descriptors whose meaning is more specific than "Carcinoma, Bronchogenic".
This graph shows the total number of publications written about "Carcinoma, Bronchogenic" by people in this website by year, and whether "Carcinoma, Bronchogenic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2015 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Carcinoma, Bronchogenic" by people in Profiles.
-
50th Anniversary Landmark Commentary on Jensik RJ, Faber LP, Kittle CF. Segmental resection for bronchogenic carcinoma. Ann Thorac Surg 1979;28:475-83. Ann Thorac Surg. 2015 Sep; 100(3):776-7.
-
Lysyl oxidase expression in bronchogenic carcinoma. Am J Surg. 2005 Mar; 189(3):297-301.
-
Neoplasms metastatic to parathyroid glands. South Med J. 1988 Nov; 81(11):1467.
-
Phase II trial of therapy with etoposide, 5-fluorouracil by continuous infusion, cisplatin, and simultaneous split-course radiation in stage III non-small cell bronchogenic carcinoma. NCI Monogr. 1988; (6):331-4.
-
Continuous infusion of etoposide, bolus administration of cisplatin, and simultaneous radiation therapy in previously treated patients with small cell bronchogenic carcinoma. NCI Monogr. 1988; (6):323-5.
-
Phase II trial of mitomycin, vindesine, and hexamethylmelamine in metastatic non-small cell bronchogenic carcinoma. Cancer Treat Rep. 1986 Dec; 70(12):1447-8.
-
Phase II trial of etoposide, cisplatin, continuous infusion 5-fluorouracil, and simultaneous split-course radiation therapy in stage III non-small-cell bronchogenic carcinoma. Semin Oncol. 1986 Sep; 13(3 Suppl 3):115-20.
-
Intensive induction treatment of small cell bronchogenic carcinoma with cyclophosphamide, methotrexate, and etoposide. Cancer Treat Rep. 1985 Sep; 69(9):1007-9.
-
Analysis of human small cell lung cancer differentiation antigens using a panel of rat monoclonal antibodies. Cancer Res. 1984 May; 44(5):2052-61.
-
Phase II trial of bisantrene for unresectable non-small cell bronchogenic carcinoma: an Illinois Cancer Council study. Cancer Treat Rep. 1983 Sep; 67(9):841-2.